Edward M. Kaye

Ed Kaye, a pediatric neurologist, is the chief executive officer and a director of Stoke Therapeutics. Ed previously served as CEO of Sarepta Therapeutics, where he led the successful push to win FDA approval of Exondys 51, a pioneering drug for Duchenne muscular dystrophy. Before taking on the CEO role at Sarepta, he served as the company’s chief medical officer for six years, leading the drive to develop Exondys 51. He also served on Sarepta’s board of directors. Earlier in his career, Ed spent 10 years at Genzyme Corporation, most recently as group vice president of clinical development, where he supervised clinical research in programs focused on lysosomal storage disease and genetic neurological disorders. At Genzyme, Ed also held various roles, including vice president of medical affairs for lysosomal storage diseases, vice president of clinical research, and interim head of PGH global medical affairs. Ed currently serves as a member of the boards of directors at Cytokinetics, Inc. and the Massachusetts Biotechnology Council. Prior to entering the biotech industry, Ed trained in pediatrics, pediatric neurology, and biochemical genetics. He was on the research staff at Massachusetts General Hospital and Tufts University Medical Center and was the chief of biochemical genetics at the Children’s Hospital of Philadelphia. He remains on the pediatric neurology staff at Boston Children’s Hospital. Ed earned his B.S. in biology from Loyola University and earned his M.D. at the Loyola University Stritch School of Medicine.